Acquisition of Exclusive Manufacturing and Marketing Rights for DOTATOC
Acquisition of Exclusive Manufacturing and Marketing Rights for DOTATOC
AsiaNet 54322
GARCHING, Germany, Sep. 19, 2013 /PRN=KYODO JBN/ --
- In-licensing of superior DOTA-Tyr3-octreotide
- Pharmaceutical developmentfor treatment of NETs
- Excellent pharmacokinetic properties
ITM Isotope Technologies Munich AG (ITM) today announced that it has
entered into an exclusive licensing agreement with Progenics Pharmaceuticals
Inc. for pharmaceutical development and commercialization of radiolabeled
DOTA-conjugated somatostatin analogue DOTA-[Tyr3]-octreotide (DOTATOC known as
Edotreotide) for human oncology therapeutic use. Radiolabeled DOTATOC is a
superior agent for safe and highly effective radionuclide therapy of
somatostatin receptor positive tumors which offers excellent pharmacokinetic
properties and highest affinity to somatostatin receptor subtypes 2 and 5.
Scope of license agreement
The sublicense granted by Progenics Pharmaceuticals Inc. covers exclusive
worldwide manufacturing and marketing rights of DOTATOC and certain
radiolabeled DOTATOC for human oncology therapeutic use except the countries
Albania, Algeria, Bahrain, Bulgaria, Cyprus, Greece, Iran, Iraq, Kuwait,
Lebanon, Oman, Qatar, Romania, Saudi Arabia, Syria, Turkey and United Arab
Emirates. Further terms of the agreement were not disclosed.
Pharmaceutical development
ITM affiliate ITG Isotope Technologies Garching GmbH will develop
radiolabeled DOTATOC for treatment of metastatic neuroendocrine tumors. In
addition, DOTATOC as precursor is now available and will be distributed in GMP
quality in cooperation with a leading supplier of advanced chemicals for
nuclear medicine.
About DOTATOC
DOTATOC or Edotreotide is a superior synthetic somatostatin analog which
binds perfectly to somatostatin receptors predominantly overexpressed in
neuroendocrine tumors (NETs). NETs are rare kind of tumors which arise from
neuroendocrine cells and may occur in different parts of the body.
DOTA-chelated peptide Edotreotide exhibits excellent pharmacokinetic
properties and can be efficiently radiolabeled with medical radionuclides. Its
excellent therapeutic properties have been successfully started in various
clinical trials.
About ITM Isotope Technologies Munich AG
The itm Group is the leading company for the development, production and
worldwide distribution of highly effective radionuclides for diagnosis and
therapy as well as radionuclide-based medical devices. Its commitment to
shaping the future of theranostics is built on robust platform technologies and
innovative new generation radioisotopes which assure safety, performance and
security of supply!
CONTACT: Christopher Morin
Manager
Marketing & Corporate Communications
Phone: +49-89-289-13915
Mail: Christopher.Morin@itg-garching.de
Steffen Schuster
CEO
Phone: +49-89-289-13970
Mail: Steffen.Schuster@itm.ag
ITM Isotope Technologies Munich AG
Aufsichtsratsvorsitzender - Udo J. Vetter
Vorstandsvorsitzender - Steffen Schuster
Sitz der Gesellschaft
Lichtenbergstr. 1, 85748 Garching - HG Muenchen - HRB 154944
SOURCE: ITM Isotope Technologies Munich AG
本プレスリリースは発表元が入力した原稿をそのまま掲載しております。また、プレスリリースへのお問い合わせは発表元に直接お願いいたします。
このプレスリリースには、報道機関向けの情報があります。
プレス会員登録を行うと、広報担当者の連絡先や、イベント・記者会見の情報など、報道機関だけに公開する情報が閲覧できるようになります。